Ontology highlight
ABSTRACT:
SUBMITTER: Miyajima N
PROVIDER: S-EPMC7561255 | biostudies-literature | 2013 Dec
REPOSITORIES: biostudies-literature
Miyajima Naoto N Tsutsumi Shinji S Sourbier Carole C Beebe Kristin K Mollapour Mehdi M Rivas Candy C Yoshida Soichiro S Trepel Jane B JB Huang Ying Y Tatokoro Manabu M Shinohara Nobuo N Nonomura Katsuya K Neckers Len L
Cancer research 20131011 23
The proto-oncogene MET is aberrantly activated via overexpression or mutation in numerous cancers, making it a prime anticancer molecular target. However, the clinical success of MET-directed tyrosine kinase inhibitors (TKI) has been limited due, in part, to mutations in the MET kinase domain that confer therapeutic resistance. Circumventing this problem remains a key challenge to improving durable responses in patients receiving MET-targeted therapy. MET is an HSP90-dependent kinase, and in thi ...[more]